RHONDA RUSHING: Open Payments
NPI 1942894464 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,079 in 111 payments from 16 companies in 2025. Trend: 2023 $1,981 · 2024 $1,768 · 2025 $2,079
Food & beverage: $2,031Education: $48
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 15 | $310 |
| ABBVIE INC. | 16 | $289 |
| E.R. Squibb & Sons, L.L.C. | 15 | $285 |
| Alkermes, Inc. | 14 | $241 |
| Vanda Pharmaceuticals Inc. | 9 | $185 |
| Otsuka America Pharmaceutical, Inc. | 11 | $165 |
| Lundbeck LLC | 8 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $141 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
Products named: REXULTI, VRAYLAR, COBENFY, ARISTADA, FANAPT, INVEGA SUSTENNA, CAPLYTA, SPRAVATO.
Industry payments across LA — which companies pay providers there.
